Martin Mense

SVP Drug Discovery
Cystic Fibrosis Foundation

Poster(s):

• (589) Combination treatment with CC-90009 and ELX-02 restores functional CFTR in patient derived intestinal organoids bearing PTC variants.
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (592) Ribosome profiling reveals distinct translation termination kinetics and efficiency between FRT and 16HBE cells
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (613) Understanding synergy in nonsense suppression therapy for CFTR nonsense mutations
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (614) Sensitized high throughput screening for translational readthrough promoters in the context of the native CFTR R1162X gene
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (631) Comparing F508del CFTR modulator responses in human primary enteric monolayer (hPEM) and human bronchial epithelial (hBE) cultures
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (634) Generation of a CFTR R1162X “TAG” model and comparison of readthrough to the naturally occurring R1162X “TGA”
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (635) Genome-Wide screen to uncover genes promoting Premature Termination Codon (PTC) readthrough.
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (641) Building Towards the Future: The CFFT Lab as an expanding repository of primary cells with rare genotypes for CF research
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (663) Modulation of CFTR intron 22 alternative polyadenylation (ApA) usage may have therapeutic potential for the treatment of certain 3’ CFTR PTC variants.
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET

• (676) A multi-center approach to optimize and validate a robust CFTR-specific immunolabeling protocol
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET